Neurocrine biosciences reports fourth quarter and fiscal 2023 financial results and provides financial expectations for 2024

Ingrezza® (valbenazine) fourth quarter and full year 2023 net product sales of $500 million and $1.84 billion, representing year-over-year growth of 25% and 29% respectively ingrezza® (valbenazine) full year 2024 net product sales guidance of $2.1 - $2.2 billion crinecerfont fda regulatory submission anticipated in the second quarter for the treatment of congenital adrenal hyperplasia in adults and pediatrics san diego , feb. 7, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the fourth quarter and full year ended december 31, 2023 and provided financial guidance for 2024. "i'm exceptionally proud of the progress we made with ingrezza last year, helping more patients than ever before treat their tardive dyskinesia.
NBIX Ratings Summary
NBIX Quant Ranking